Skip to main content
Device Global Header

Subscribe
or Renew

Advanced Search

This article is available to subscribers. Subscribe now. Already have an account? Sign in

Review ArticleMedical ProgressFree Preview

Renal-Cell Carcinoma

List of authors.
  • Robert J. Motzer, M.D.,
  • Neil H. Bander, M.D.,
  • and David M. Nanus, M.D.

Renal-cell carcinoma is characterized by a lack of early-warning signs (which results in a high proportion of patients with metastases), diverse clinical manifestations, and resistance to radiotherapy and chemotherapy, and there is a potential role for immunomodulation in the inhibition of tumor growth. In this review we discuss recent developments in epidemiology, histologic classification, tumor biology, methods of diagnosis and staging, surgical techniques, and immunotherapy for patients with metastatic disease.EpidemiologyRenal-cell carcinoma accounts for 2 percent of all cancers.1 Its incidence varies among countries by a factor of 20 among men and by a factor of 10 among women, . . .

Continue reading this article

Select an option below:

Create your account to get 2 free subscriber-only articles each month.

Get Free Access Now Subscribe For Full Access

Already have an account?

Sign In

Print subscriber?

Activate your online access.

Funding and Disclosures

We are indebted to Victor Reuter, M.D., Susan Hilton, M.D., Zuo-feng Zhang, M.D., Ph.D., and W. Marston Linehan, M.D., for their review of the manuscript.

Author Affiliations

From the Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center (R.J.M., D.M.N.); the Department of Urology, New York Hospital (N.H.B.); and the Departments of Medicine (R.J.M., D.M.N.) and Urology (N.H.B.), Cornell University Medical College — all in New York.

Address reprint requests to Dr. Motzer at Memorial Hospital, 1275 York Ave., New York, NY 10021.

Print Subscriber? Activate your online access.